

Vanda Pharmaceuticals Inc.  
Form 8-K  
September 08, 2011

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): September 8, 2011  
VANDA PHARMACEUTICALS INC.  
(Exact name of Registrant as specified in its charter)**

**Delaware**

**001-34186**

**03-0491827**

(State or other Jurisdiction of  
Incorporation)

(Commission File No.)

(IRS Employer Identification No.)

**9605 Medical Center Drive  
Suite 300  
Rockville, Maryland**

**20850**

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: **(240) 599-4500**

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01. Regulation FD Disclosure**

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer of Vanda Pharmaceuticals Inc. (the Company or Vanda ) will be making a corporate presentation at the Stifel Nicolaus Global Healthcare Conference ( the Global Healthcare Conference ) in Boston, MA on Thursday, September 8, 2011 at 4:25 p.m. Eastern Time. The slides that will be used for such presentation are furnished as Exhibit 99.1 to this Current Report on Form 8-K. Vanda issued a press release on August 31, 2011 announcing the Company s participation at the Global Healthcare Conference, which is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

Various statements to be made during the presentation, including statements in the slides furnished as Exhibit 99.1 to this Form 8-K, are forward-looking statements under the securities laws. Words such as, but not limited to, believe, expect, anticipate, estimate, intend, plan, targets, likely, will, would, and could, or the negative of similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.

Important factors that could cause actual results to differ materially from those reflected in the Company s forward-looking statements include, among others: the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda s ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vanda s clinical trials; a failure of Vanda s products, product candidates, or partnered products to be demonstrably safe and effective; Vanda s failure to obtain regulatory approval for its products or product candidates or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda s products, product candidates or partnered products in the marketplace, or a failure to become or remain profitable; Vanda s expectations regarding trends with respect to its costs and expenses; Vanda s inability to obtain the capital necessary to fund additional research and development activities; Vanda s failure to identify or obtain rights to new products or product candidates; Vanda s failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; limitations on Vanda s ability to utilize some or all of its prior net operating losses and research and development credits; a loss of any of Vanda s key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda s products or product candidates under its license and sublicense agreements and other factors that are described in the Risk Factors and Management s Discussion and Analysis of Financial Condition and Results of Operations sections of Vanda s Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, which are on file with the SEC and available on the SEC website at [www.sec.gov](http://www.sec.gov). In addition to the risks described above and in Vanda s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda s results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information conveyed during the presentation and in the slides attached as Exhibit 99.1 to this Form 8-K will be provided only as of the date of the Global Healthcare Conference, and the Company undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements contained in such slides or presentation from and after the date of the Global Healthcare Conference whether as a result of new information, future events or otherwise.

The information in Item 7.01 of this Current Report on Form 8-K and the Exhibits attached hereto shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	Presentation Slides
99.2	Press Release

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VANDA PHARMACEUTICALS INC.

By: /s/ James Kelly  
Name: James Kelly  
Title: Chief Financial Officer

Dated: September 8, 2011